Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. - Wikidata - wikimedia - TriplyDB

Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

http://www.wikidata.org/entity/Q35076961

about

Prime-boost approaches to tuberculosis vaccine development LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Development of replication-competent viral vectors for HIV vaccine delivery.The influence of delivery vectors on HIV vaccine efficacy Transmitted/founder simian immunodeficiency virus envelope sequences in vesicular stomatitis and Semliki forest virus vector immunized rhesus macaques.In vitro evolution of high-titer, virus-like vesicles containing a single structural protein.Rhabdovirus-based vaccine platforms against henipaviruses Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.Recent advances in molecular medicine techniques for the diagnosis, prevention, and control of infectious diseases.HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory.Technical considerations for the generation of novel pseudotyped viruses DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination

P2860

Q27024526-EBECE9B2-9656-4B30-A7FB-72E77C62E592 Q28118448-219489DA-B01E-4B61-9AD4-B71A6BCF79BD Q30370147-73521801-1667-4EEF-9C35-49B6BDFD24E9 Q33694226-022824D7-6575-43AC-B0C9-1C827271B3A7 Q34077543-EA54B765-4779-44D7-8A03-D9D9F9EDBE02 Q34433975-5DDE3D7B-6203-4DD8-A15C-A82A3A39B3A6 Q34601498-93F366EF-44EB-4A57-AE78-25C90FBA18BF Q34992537-E0DBBC3D-9A69-4BD2-A290-3EA9E3F5387E Q35069151-CBEF28D1-880B-4B72-A64F-2F4DEEABECF1 Q35156935-7F8D4F10-FA58-402D-855E-9F0411BD953F Q35868091-0F065D72-9492-4D37-A7BF-4EE80FD28B3C Q35914362-89D72933-D1C5-4711-932A-DDA69A5498F3 Q35985519-2E4FA2C5-82E6-413F-998B-77C0AA6EC642 Q36007614-F1F06D63-B73A-4898-8DAF-A866B43DF19C Q37395174-7781F146-25CA-4153-879F-1EBFEB25417A Q37522856-BF49329C-E33C-4E91-8E0B-649FFD41429D Q37621530-84CDD469-F880-4E5E-B3E3-38F3CFAEA1F4 Q37625296-F209185F-BE6B-4851-82CE-97EB335DC34A Q38075857-8096E15F-F6B6-4154-85E4-F34F6A63ACC4 Q38105946-F80F9B6F-E775-42E1-9CA5-7F6142086DC0 Q38811582-B8D3D8A4-8206-4ADC-BD68-F7FFE3627F04 Q38846017-7DECBCA8-B95D-4D30-A3CB-DAC8FB57BB23 Q38886667-4D5F0CDF-16AA-4FCD-884A-C59B92D3CADE Q41820076-34E2555C-0054-4081-836F-2EF9FE3500CA Q45323639-BAE61088-9667-4116-B053-916CF264DC7C Q57275154-75A790B7-8A5B-4829-9F19-0B77BAFEF642 Q58711069-7E3AA11E-0B0A-49E0-B032-77879F36F65B

P2860

Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

http://www.wikidata.org/entity/Q35076961

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Significant protection against ...... w prime-boost vaccine regimen.

@ast

Significant protection against ...... w prime-boost vaccine regimen.

@en

type

label

Significant protection against ...... w prime-boost vaccine regimen.

@ast

Significant protection against ...... w prime-boost vaccine regimen.

@en

prefLabel

Significant protection against ...... w prime-boost vaccine regimen.

@ast

Significant protection against ...... w prime-boost vaccine regimen.

@en

P1433

Q35076961-EF44F8FD-BD7C-4199-8DC7-4F8BAE71FFAE

P1476

Q35076961-6D6C41D9-3D1C-4149-B414-CBBFA6FC79BC

P2093

Q35076961-30A6928B-E9ED-4193-A347-8D177F8D8CE1

Q35076961-39DDF539-F5BE-44E5-BF9D-D90DCFA4C014

Q35076961-48A0519F-2287-4C10-8D3B-2E7DE3F117CE

Q35076961-5E2E0E67-AC3D-46B4-9925-F22F73ACE45B

Q35076961-69741872-9CB0-45F4-9851-652B114A7083

Q35076961-6B77EB18-2065-4059-8C5E-06398B2E9C33

Q35076961-757F4B54-3DF5-49E6-AA2B-3D2D926CBA6D

Q35076961-843C8A16-8A88-456F-88A2-A6C804214329

Q35076961-8C7E5441-3A43-40D6-91DA-0F8B832947B6

Q35076961-A9943688-E96B-41D5-A146-FD71820938F8

P2860

Q35076961-062BDC9E-085A-40D1-8F50-BB7FB6BF9B7B

Q35076961-11F0E2B8-6366-45FC-9735-F9E8A83AC600

Q35076961-156C2012-9B7A-4229-99B7-0B4AEC2D0B15

Q35076961-1650059A-4866-4F96-97A0-3D6B3FB9A0BE

Q35076961-1D4A2831-316E-4463-BBD3-03AEDE8E4798

Q35076961-1DF19DFC-2970-4FFF-B2BD-4B1B2B168FE4

Q35076961-2074A32A-1153-40DF-9EB2-6B0A4BA32FE9

Q35076961-2DB0356E-D9F6-49B6-ADD3-93BDAB64361E

Q35076961-30A5C7C2-E1AF-4B09-A4AA-6F838B6D44BF

Q35076961-30D4C497-5547-48CC-8729-E739843FA2CF

P304

Q35076961-40D32796-DAC2-483D-B81F-77C4AC4F54F2

P31

Q35076961-1079056F-871C-4C1C-817F-D5C129EA6D31

P356

Q35076961-5E21A798-CAD7-4411-BC9E-1D75090505E3

P407

Q35076961-4E1D4840-F6D0-4D4D-9634-D961475BCA2D

P433

Q35076961-30006EC2-CEEF-47E9-846A-5EA04A609A76

P478

Q35076961-D3A1A905-A6C0-4AEE-9375-2B61F7B733D5

P50

Q35076961-2C1CE779-D729-4F52-A854-D55E2FE98D73

P577

Q35076961-E7D34752-0671-4BD4-BBC3-63BCC0255CEE

P698

Q35076961-12F3EF0C-A39A-4987-A73E-BE05F36D7FE8

P921

Q35076961-86E06470-7D01-49B9-9850-0033FBDFBAB1

P932

Q35076961-9D016AA0-F6BB-48AF-A844-578C8E4C705B

P356

P1433

Journal of Virology

P1476

Significant protection against ...... w prime-boost vaccine regimen.

@en

P2093

Haili Tang

http://www.w3.org/2001/XMLSchema#string

John B Schell

http://www.w3.org/2001/XMLSchema#string

John K Rose

http://www.w3.org/2001/XMLSchema#string

Kapil Bahl

http://www.w3.org/2001/XMLSchema#string

Kathryn Diller

http://www.w3.org/2001/XMLSchema#string

Linda Buonocore

http://www.w3.org/2001/XMLSchema#string

Meredith Hunter

http://www.w3.org/2001/XMLSchema#string

Nina F Rose

http://www.w3.org/2001/XMLSchema#string

Preston A Marx

http://www.w3.org/2001/XMLSchema#string

Ratish Gambhira

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a major co-receptor for primary isolates of HIV-1

Hybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectors

Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species

Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.

P304

5764-5772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.00342-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

David C Montefiori

P577

2011-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21490100

http://www.w3.org/2001/XMLSchema#string

P921

Simian immunodeficiency virus

P932

3126289

http://www.w3.org/2001/XMLSchema#string